Study looking at immunotherapy treatment, after surgery and chemotherapy, to treat patients with lung cancer

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Data is not saved in preview.
"Can immunotherapy help after surgery and chemotherapy to treat lung cancer?"
18 to 100 years old
Healthy Volunteers:
immunotherapy, lung cancer, cancer
Other study, Phase 3
This study looks at how well a type of immunotherapy, (nivolumab), after surgery and chemotherapy, work in treating patients with lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard chemotherapy.
This study requires

Please contact for details

Who can participate

Inclusion Criteria:

  • Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) 7th edition and have had negative surgical margins

  • Baseline chest computed tomography (CT) must be performed within 1 month (30 days) of randomization to ensure no evidence of disease; if clinically indicated, additional imaging studies must be performed to rule out metastatic disease

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  • Patients must be registered to the ALCHEMIST-SCREEN (ALLIANCE A151216) trial prior to randomization

  • Non-squamous tumors must be epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) wild-type (results ascertained in centrally as part of ALCHEMIST-SCREEN protocol)

  • Tumors must have PD-L1 status tested centrally as part of the ALCHEMIST-SCREEN protocol

  • Women must not be pregnant or breast-feeding

  • All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse during the treatment period and for 31 weeks after the last nivolumab infusion

  • Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements

  • No prior treatment with an immune checkpoint inhibitor (anti-programmed cell death [PD]-1, anti-PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] monoclonal antibody)

  • Patients must have adequately recovered from surgery and chemotherapy at the time of randomization

  • Minimum time between date of surgery and randomization is 4 weeks (28 days)

  • Maximum time allowed between surgery and randomization:

  • 3 months (90 days) if no chemotherapy is administered

  • 8 months (240 days) if adjuvant chemotherapy was administered

  • 10 months (300 days) if adjuvant chemotherapy and radiation therapy was administered

  • Patients must have completed and recovered from any adjuvant chemotherapy 2 or more weeks prior to randomization (6 weeks for mitomycin and nitrosoureas; 4 weeks for post-operative radiation therapy)

  • Serum aspartate transaminase (aspartate aminotransferase [AST]) and serum alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x upper limit normal

  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (except in subjects with Gilbert syndrome who must have a total bilirubin < 3.0 x ULN)

  • White blood cell (WBC) >= 2000/uL

  • Neutrophils >= 1000/uL

  • Platelets >= 100 x 10^3/uL

  • Hemoglobin >= 8 g/dL

  • Serum creatinine =< 2 x ULN

  • Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade =< 1 with the exception of alopecia, ototoxicity and neuropathy

  • Patients must not be receiving any other investigational anti-cancer agents while on study

  • Patients must not have known or suspected autoimmune disease; subjects with type I diabetes mellitus, hypothyroidism requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll

  • Patients must not have a condition requiring systemic corticosteroids equivalent to > 10 mg prednisone per day or other immunosuppressive medications within 2 weeks of randomization

  • Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

  • Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load

  • Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab

Study duration and period
Please contact for details
Recruitment period
From Sept. 6, 2016
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Research Topic
  • Stage IB Non-Small Cell Lung Carcinoma
  • Stage II Non-Small Cell Lung Cancer
  • Stage IIA Non-Small Cell Lung Carcinoma
  • Stage IIB Non-Small Cell Lung Carcinoma
  • Stage IIIA Non-Small Cell Lung Cancer

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview